MALP-2 modulated dendritic cells based immunotherapy (Helmholtz Zentrum fur Infektionsforschung/Ascenion)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMALP-2 modulated dendritic cells based immunotherapy (Helmholtz Zentrum fur Infektionsforschung/Ascenion)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsHypersensitivityAutoimmune DiseasesNeoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHelmholtz Zentrum fur Infektionsforschung GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHelmholtz Zentrum fur Infektionsforschung GmbHAscenion
Active IndicationsN/A
Inactive IndicationsHypersensitivityAutoimmune DiseasesNeoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A